Condition
Ulcerative Colitis
Clear, practical articles to help you understand Ulcerative Colitis symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Skyrizi vs Stelara for Ulcerative Colitis: A Comparison
Skyrizi and Stelara are two interleukin-pathway biologics increasingly used for moderate-to-severe ulcerative colitis. Skyrizi gained UC approval in June 2024, joining Stelara in the IL-23 targeting category. The two drugs take meaningfully different approaches. Skyrizi blocks only IL-23. Stelara blocks both IL-12 and IL-23. For Crohn's, the SEQUENCE head-to-head trial showed Skyrizi's p19 selectivity outperformed Stelara on endoscopic endpoints, and UC patients often want to know whether similar logic applies to their disease. This guide walks through the current evidence and practical considerations for the skyrizi vs stelara ulcerative colitis decision.
Skyrizi vs Remicade for Ulcerative Colitis: Patient Guide
Skyrizi and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Skyrizi is a newer IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the skyrizi vs remicade ulcerative colitis decision.
Skyrizi vs Omvoh for Ulcerative Colitis: A Comparison
Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Omvoh gained UC approval first in October 2023 based on LUCENT-1 and LUCENT-2. Skyrizi followed in June 2024 based on INSPIRE and COMMAND. Patients comparing these two within-class UC options often weigh maintenance dosing, bowel urgency outcomes, and trial design. This guide walks through the skyrizi vs omvoh ulcerative colitis comparison.
Skyrizi vs Humira for Ulcerative Colitis: What to Know
Skyrizi and Humira are two AbbVie biologics for moderate-to-severe ulcerative colitis, but they work through very different mechanisms. Humira is the established anti-TNF standard with more than a decade of UC experience. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on the INSPIRE induction and COMMAND maintenance trials. For UC patients choosing between these drugs, the decision often comes down to mechanism, administration preferences, and expected long-term safety. This guide walks through the skyrizi vs humira ulcerative colitis decision.
Skyrizi vs Entyvio for Ulcerative Colitis: A Comparison
Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs but through very different mechanisms. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing its superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or are looking for alternatives to anti-TNF therapy. This guide walks through the skyrizi vs entyvio ulcerative colitis comparison.
Simponi vs Tremfya for Ulcerative Colitis: Comparing Biologics
Simponi and Tremfya represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for UC in September 2024 based on QUASAR and ASTRO. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with distinctive induction flexibility. This guide walks through the simponi vs tremfya ulcerative colitis comparison.
Simponi vs Stelara for Ulcerative Colitis: How They Compare
Simponi and Stelara are two subcutaneous biologics for moderate-to-severe ulcerative colitis that work through fundamentally different mechanisms. Simponi (golimumab) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the simponi vs stelara ulcerative colitis decision.
Simponi vs Skyrizi for Ulcerative Colitis: A Patient Guide
Simponi and Skyrizi represent two different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Skyrizi (risankizumab) is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the simponi vs skyrizi ulcerative colitis comparison.
Simponi vs Remicade for Ulcerative Colitis: Key Differences
Simponi and Remicade are two anti-TNF biologics for moderate-to-severe ulcerative colitis that take different administration routes. Simponi (golimumab) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, so their mechanisms are closely related, but the administration difference and dose escalation options shape the practical comparison. This guide walks through the simponi vs remicade ulcerative colitis decision.
Simponi vs Omvoh for Ulcerative Colitis: Which Is Better?
Simponi and Omvoh represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2, making it the first IL-23 p19-selective biologic approved for UC. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and distinctive urgency data. This guide walks through the simponi vs omvoh ulcerative colitis comparison.
Simponi vs Humira for Ulcerative Colitis: Comparing Anti-TNFs
Simponi and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe ulcerative colitis. Both block TNF-alpha through fully human IgG monoclonal antibody structures, so their mechanisms are closely related. The main practical differences come down to dosing frequency (monthly for Simponi vs every other week for Humira), biosimilar availability, and trial data. This guide walks through the simponi vs humira ulcerative colitis comparison.
Simponi vs Entyvio for Ulcerative Colitis: A Comparison
Simponi and Entyvio take very different mechanistic approaches to moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic that targets alpha-4-beta-7 integrin. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with favorable systemic safety. This guide walks through the simponi vs entyvio ulcerative colitis comparison.